Neluxicapone
Overview[edit]
Neluxicapone is a pharmaceutical compound that acts as a catechol-O-methyltransferase (COMT) inhibitor. It is primarily used in the treatment of Parkinson's disease, where it helps to prolong the effect of levodopa, a common medication used to manage the symptoms of this neurodegenerative disorder.
Mechanism of Action[edit]
Neluxicapone works by inhibiting the enzyme catechol-O-methyltransferase, which is responsible for the breakdown of catecholamines such as dopamine. By inhibiting this enzyme, neluxicapone increases the availability of dopamine in the brain, thereby enhancing the therapeutic effects of levodopa in patients with Parkinson's disease.
Pharmacokinetics[edit]
Neluxicapone is administered orally and is absorbed through the gastrointestinal tract. It undergoes hepatic metabolism and is excreted primarily through the kidneys. The pharmacokinetic profile of neluxicapone allows for sustained inhibition of COMT, making it an effective adjunct therapy in the management of Parkinson's disease.
Clinical Use[edit]
In clinical practice, neluxicapone is used in combination with levodopa and a decarboxylase inhibitor to improve motor function in patients with Parkinson's disease. It is particularly beneficial in reducing "off" periods, where the effects of levodopa wear off before the next dose is due.
Side Effects[edit]
Common side effects of neluxicapone include nausea, dizziness, and dyskinesia. As with other COMT inhibitors, there is a risk of liver toxicity, and liver function should be monitored during treatment.
